Spyre’s SPY072 Shows Mixed Results in Rheumatoid Arthritis Trial — Spyre Therapeutics, Inc.

Event summary

Both doses of SPY072 demonstrated statistically significant benefits compared to placebo on primary, secondary, and exploratory endpoints in the RA sub-study of the SKYWAY Phase 2 trial.
SPY072 was well tolerated with adverse event rates comparable to placebo.
The magnitude of effect did not meet Spyre’s internal bar to prioritize monotherapy development of SPY072 in rheumatoid arthritis (RA).
Topline data for SPY072 in psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) are expected in Q4 2026.
Topline data for SPY072 in combination with IL17-A/F in hidradenitis suppurativa (HS) are expected in late 2027 or early 2028.

The big picture

Spyre Therapeutics’ SPY072 showed promising but not definitive results in the rheumatoid arthritis sub-study of the SKYWAY Phase 2 trial. While the drug demonstrated statistically significant benefits and a favorable safety profile, it did not meet the company’s internal bar for monotherapy development in RA. This shifts Spyre’s focus towards combination therapies and other autoimmune indications, highlighting the strategic importance of its TL1A antibodies in a competitive biotech landscape. The upcoming results for SPY072 in PsA, axSpA, and HS will be critical in determining the company’s next steps and market positioning.

What we're watching

Combination Strategy: Whether Spyre can leverage the broad potential of TL1A antibodies in combination therapies to offset the lack of monotherapy prioritization in RA.
Pipeline Progress: The pace at which Spyre can deliver topline results for SPY072 in PsA and axSpA, and the SKYLIGHT trial in HS.
Market Positioning: How Spyre positions its TL1A antibodies against competitors in the autoimmune disease space.